London, UK & Stanford, USA – September 8, 2023 – In a groundbreaking discovery that could fundamentally alter the fight against glioblastoma, the most aggressive and common adult brain cancer, an international consortium of scientists has unveiled a critical mechanism driving its rapid and often treatment-resistant growth. The research, spearheaded by the Cancer Grand Challenges team eDyNAmiC, reveals that enigmatic circles of DNA known as extrachromosomal DNA (ecDNA) play an early and pivotal role in the disease’s development, presenting an unprecedented "window of opportunity" for earlier diagnosis and more effective therapeutic strategies.
Published today in the prestigious journal Cancer Discovery, these findings represent a significant leap forward in understanding glioblastoma’s elusive origins. For the first time, scientists have demonstrated that these rogue ecDNA rings, carrying potent cancer-driving genes, frequently emerge in the nascent stages of glioblastoma’s formation—sometimes even before a full-fledged tumour has manifested. This premature appearance appears to be a critical determinant in setting the stage for the cancer’s notoriously rapid progression, remarkable adaptability, and disheartening resistance to current treatments.
The study, a testament to the power of interdisciplinary collaboration, was co-led by Dr. Benjamin Werner, a group leader at Queen Mary University of London, and Professor Paul Mischel, the Fortinet Founders Professor at Stanford University. Both are integral members of the Cancer Grand Challenges team eDyNAmiC, a global initiative dedicated to cracking the toughest nuts in cancer research. Further significant contributions came from Professor Charlie Swanton, Deputy Clinical Director at The Francis Crick Institute. Their collective efforts illuminate a previously obscured pathway in glioblastoma evolution, offering a glimmer of hope where historically there has been little.
The Dire Reality of Glioblastoma: A Formidable Foe
Glioblastoma multiforme (GBM) stands as one of oncology’s most formidable challenges. Affecting approximately 2 to 3 people per 100,000 in the United States and Europe, it is the most aggressive primary malignant brain tumour. Patients diagnosed with glioblastoma face a grim prognosis, with a median survival rate of only around 14 months, a figure that has seen little improvement over the past several decades despite advances in surgical techniques, radiation therapy, and chemotherapy. The standard treatment regimen, involving surgery followed by radiation and concomitant temozolomide chemotherapy, often yields temporary relief, but recurrence is almost inevitable, frequently with increased resistance to subsequent therapies.
The aggressive nature of glioblastoma stems from several factors: its highly invasive capacity, allowing tumour cells to infiltrate healthy brain tissue, making complete surgical removal virtually impossible; its remarkable cellular heterogeneity, meaning different cells within the same tumour can possess distinct genetic mutations and behaviours; and the formidable blood-brain barrier, which severely restricts the delivery of most therapeutic agents to the tumour site. These inherent challenges underscore the urgent and desperate need for novel approaches that can detect the disease earlier, track its progression with greater precision, and develop treatments that circumvent its inherent resistance mechanisms. The discovery regarding ecDNA offers a tantalizing prospect for addressing these very hurdles.
Unravelling the Enigma of Extrachromosomal DNA (ecDNA)
For years, scientists have focused on genetic mutations within chromosomes as the primary drivers of cancer. However, a growing body of evidence points to another, more mysterious player: extrachromosomal DNA, or ecDNA. These small, circular fragments of DNA exist outside the main chromosomal structure of a cell, carrying genes that can be amplified to high copy numbers. Unlike chromosomal DNA, which is inherited and stably maintained, ecDNA is highly dynamic, capable of rapid replication, redistribution to daughter cells, and often carrying multiple copies of oncogenes—genes that promote cancer growth. This fluidity allows cancer cells to quickly adapt to changing environments, including therapeutic pressures, making ecDNA a powerful engine of tumour evolution and drug resistance.
The complex and enigmatic role of ecDNA in various adult and paediatric cancers, including glioblastoma, has long intrigued researchers. Recognizing its potential as a critical, yet poorly understood, factor in cancer progression, the Cancer Grand Challenges initiative identified deciphering ecDNA’s role as one of the toughest problems facing contemporary cancer research. This ambitious initiative, co-founded by Cancer Research UK and the National Cancer Institute in the United States, pools global expertise and resources to tackle high-impact, unsolved cancer questions.
In 2022, they provided a substantial $25 million grant to establish team eDyNAmiC—an international, cross-disciplinary consortium comprising experts in cancer biology, clinical research, evolutionary biology, computer science, and mathematics. Their mission: to systematically decipher the role of ecDNA across various cancer types and, crucially, to identify actionable strategies to target it. The current study on glioblastoma marks a pivotal advance in team eDyNAmiC’s ongoing work, providing concrete evidence of ecDNA’s early and driving influence in one of the deadliest cancers.
Excavating a Tumour’s Past: An "Archaeological" Approach
To unravel the evolutionary history of ecDNA in glioblastoma, team eDyNAmiC and their collaborators employed an innovative, multi-faceted methodology. They integrated vast amounts of genomic and advanced imaging data meticulously collected from glioblastoma patients. This comprehensive dataset was then fed into sophisticated computational models designed to simulate the evolution of ecDNAs across both space and time within the tumour microenvironment.
Dr. Benjamin Werner eloquently described their investigative approach as akin to that of an archaeologist. "We studied the tumours much like an archaeologist would," he explained. "Rather than taking a single sample, we excavated multiple sites around the tumour, allowing us to build computational models describing how they evolved. We simulated millions of different scenarios to reconstruct how the earliest ecDNAs emerged, spread, and drove tumour aggressiveness, giving us a clearer picture of the tumour’s origins and progression." This multi-site sampling strategy, combined with advanced bioinformatics, allowed the researchers to overcome the limitations of traditional single-biopsy analyses, which often provide only a snapshot of a highly dynamic and heterogeneous tumour. By piecing together a timeline of genetic changes from various tumour regions, they could effectively "rewind" the clock of glioblastoma development.
The computational modelling was crucial for discerning the sequence of events. By simulating countless evolutionary pathways, the researchers could identify the most probable scenarios for ecDNA emergence and expansion, correlating these events with the known progression of the disease. This powerful combination of empirical data and theoretical modelling provided unprecedented insights into the dynamic interplay between ecDNA and tumour evolution.
Key Findings: EGFR and the Genesis of Aggression
The detailed analysis yielded several critical insights into glioblastoma’s evolutionary trajectory. Foremost among them was the revelation that the vast majority of ecDNA rings identified in glioblastoma tumours contained amplified copies of the EGFR gene. The Epidermal Growth Factor Receptor (EGFR) is a well-known oncogene, a gene that, when overactive or mutated, can drive uncontrolled cell growth and division. In healthy cells, EGFR plays a vital role in regulating cell proliferation, differentiation, and survival. However, in cancer, its dysregulation acts as a powerful accelerator.
Crucially, the study demonstrated that EGFR ecDNA appeared remarkably early in the cancer’s evolution, often predating the full formation of a discernible tumour in some patients. This early arrival suggests that EGFR ecDNA is not merely a consequence of established cancer but an initial, fundamental driver, potentially initiating the transformation of normal brain cells into cancerous ones.
Furthermore, the researchers observed that these EGFR ecDNA rings frequently accumulated additional genetic alterations, such as the EGFRvIII variant. EGFRvIII is a constitutively active mutant form of the EGFR protein, meaning it is permanently "switched on," leading to even more aggressive cell growth and signalling independent of external growth factors. The acquisition of such variants on ecDNA was strongly correlated with increased tumour aggressiveness and a heightened resistance to standard therapeutic interventions. This sequential accumulation of genetic changes on ecDNA provides a clear molecular explanation for glioblastoma’s rapid progression and its ability to evade treatment.
A Window of Opportunity for Intervention
The discovery of EGFR ecDNA’s early emergence, followed by the acquisition of more aggressive variants, highlights a critical "window of opportunity" for disease management. Dr. Magnus Haughey, a postdoctoral researcher in Dr. Werner’s group and one of the paper’s lead authors, underscored this potential. "These subtle mechanisms show that there may be a window of opportunity to detect and treat the disease between the first appearance of EGFR ecDNA and the emergence of these more aggressive variants," he suggested.
This implies that if scientists can develop a reliable, non-invasive test—such as a blood test or "liquid biopsy"—to detect the presence of early EGFR ecDNA, it could enable clinicians to intervene at a much earlier stage, potentially before the disease becomes entrenched, highly aggressive, and resistant to existing therapies. Such a test would represent a paradigm shift for glioblastoma diagnosis, moving from reactive detection of symptomatic, advanced tumours to proactive screening and early intervention.
The study also confirmed that ecDNA can carry more than one cancer-driving gene simultaneously. This intricate genetic payload can uniquely shape how individual tumours evolve and respond to treatment, emphasizing the profound value of tailoring therapeutic strategies based on a tumour’s specific ecDNA profile. This concept aligns perfectly with the burgeoning field of precision medicine, where treatments are customized to the genetic makeup of a patient’s tumour.
Expert Perspectives: A Unified Vision of Hope
The implications of these findings resonated strongly with the research leaders and funding bodies involved.
Professor Charlie Swanton, a leading authority on cancer evolution, emphasized the transformative potential: "These findings suggest that ecDNA is not just a passenger in glioblastoma, but an early and powerful driver of the disease. By tracing when and how ecDNA arises, we open up the possibility of detecting glioblastoma much earlier and intervening before it becomes so aggressive and resistant to therapy. I hope this might help to drive a new era in how we diagnose, track and treat this devastating cancer." His words reflect a cautious but profound optimism, acknowledging the long road ahead but celebrating a crucial first step.
Professor Paul Mischel, whose laboratory has been at the forefront of ecDNA research, echoed this sentiment, highlighting the actionable nature of the discovery. "These findings reveal an important new insight into the role of ecDNA in tumour development and progression," he stated. "Previous work from our collaborative team and other researchers, has shown that ecDNA can arise early in tumor development, including at the stage of high-grade dysplasia, and it can also arise later to drive tumor progression and treatment resistance. The findings here show that in glioblastoma, there is an early event driven by ecDNA that could potentially be more actionable, raising the possibility that glioblastoma is another cancer for which earlier detection and intervention based upon ecDNA may be possible."
Dr. David Scott, Director of Cancer Grand Challenges, lauded the study as a prime example of the initiative’s mission. "This study exemplifies the bold, boundary-pushing science Cancer Grand Challenges was created to support," he remarked. "By unravelling the evolutionary history of ecDNA in glioblastoma, team eDyNAmiC is not only deepening our understanding of one of the most devastating cancers but also illuminating new paths for earlier detection and treatment. It’s a powerful reminder that when we bring together diverse disciplines and global talent, we can begin to solve the toughest problems facing cancer research." His statement underscores the strategic importance of investing in collaborative, ambitious projects to tackle the most intractable problems in oncology.
Implications: Paving New Paths for Diagnosis, Treatment, and Prognosis
The immediate and long-term implications of this research are vast, spanning across diagnostic, therapeutic, and prognostic fronts.
Diagnostic Potential: The concept of detecting EGFR ecDNA via a liquid biopsy represents a significant paradigm shift. A simple blood test could potentially identify individuals at high risk for glioblastoma even before symptoms manifest or before a mass is visible on imaging. Developing such a test would require extensive validation to ensure high sensitivity (detecting the ecDNA when present) and specificity (not generating false positives). Challenges include the potentially low abundance of circulating tumour DNA (ctDNA) in early-stage disease and differentiating tumour-derived ecDNA from normal cellular debris. However, the potential benefit of early detection—allowing for intervention before the tumour becomes aggressive and invasive—is immense.
Therapeutic Potential: Understanding that ecDNA drives early glioblastoma growth and subsequent resistance opens new avenues for drug development. Instead of solely targeting chromosomal mutations, future therapies could focus on disrupting ecDNA itself. This could involve drugs that prevent ecDNA replication, promote its degradation, or specifically target the genes amplified on ecDNA (like EGFR) in a more effective manner than current EGFR inhibitors, which often face resistance in glioblastoma. The ability of ecDNA to carry multiple oncogenes also suggests that combination therapies, tailored to an individual tumour’s ecDNA profile, might be more effective in combating its heterogeneity and adaptability. Furthermore, new strategies to overcome the blood-brain barrier for these novel agents would be crucial.
Prognostic Potential: Tracking changes in ecDNA profiles over time could provide valuable prognostic information. An increase in EGFR ecDNA copy numbers or the emergence of aggressive variants like EGFRvIII could signal impending tumour progression or resistance to current treatment, prompting clinicians to adjust therapies proactively. This dynamic monitoring could allow for real-time, adaptive treatment strategies, moving beyond a one-size-fits-all approach.
Broader Impact and Future Directions: While this study focuses on glioblastoma, the insights gained into ecDNA’s early and driving role have broader implications for other cancer types where ecDNA is known to be present. Team eDyNAmiC’s ongoing work will continue to investigate ecDNA across a range of cancers, seeking to uncover common mechanisms and unique features that can be exploited for earlier diagnosis, more precise tracking, and smarter, more targeted treatments.
Many mysteries still remain. Researchers now plan to delve deeper into how different treatments—from chemotherapy and radiation to novel immunotherapies—affect the number and types of ecDNA in glioblastoma. Understanding these interactions will be vital for designing combination therapies that not only target the tumour but also suppress its evolutionary engines.
In conclusion, the discovery by team eDyNAmiC marks a pivotal moment in glioblastoma research. By peeling back the layers of this devastating disease’s evolution, scientists have not only revealed a fundamental driver of its aggression but also illuminated a clear path toward a future where glioblastoma might be detected earlier, understood more thoroughly, and treated with unprecedented precision. The fight against glioblastoma remains challenging, but with each groundbreaking discovery like this, the scientific community moves closer to transforming hope into tangible progress for patients worldwide.
About the Author
